HCA Healthcare, Inc. (NYSE:HCA) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lowered its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 4.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,932 shares of the company’s stock after selling 2,532 shares during the quarter. Corebridge Financial Inc.’s holdings in HCA Healthcare were worth $14,687,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of HCA. Whipplewood Advisors LLC acquired a new stake in HCA Healthcare during the fourth quarter valued at approximately $31,000. Tidemark LLC acquired a new position in shares of HCA Healthcare in the 4th quarter worth $36,000. Legacy Investment Solutions LLC acquired a new position in shares of HCA Healthcare in the 3rd quarter valued at $39,000. Activest Wealth Management lifted its stake in HCA Healthcare by 1,250.0% during the fourth quarter. Activest Wealth Management now owns 135 shares of the company’s stock valued at $40,000 after buying an additional 125 shares in the last quarter. Finally, Pinnacle Bancorp Inc. raised its holdings in shares of HCA Healthcare by 50.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 150 shares of the company’s stock valued at $45,000 after acquiring an additional 50 shares during the period. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Stock Performance

NYSE:HCA opened at $336.12 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $417.14. The firm’s fifty day simple moving average is $322.63 and its 200 day simple moving average is $341.89. The firm has a market capitalization of $82.75 billion, a PE ratio of 15.30, a PEG ratio of 1.10 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, January 24th. The company reported $6.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the company posted $5.90 EPS. On average, sell-side analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be given a dividend of $0.72 per share. The ex-dividend date is Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.86%. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s dividend payout ratio is currently 13.11%.

Insider Buying and Selling at HCA Healthcare

In related news, SVP Jennifer Berres sold 9,533 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $322.59, for a total value of $3,075,250.47. Following the completion of the transaction, the senior vice president now directly owns 15,412 shares of the company’s stock, valued at $4,971,757.08. This trade represents a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HCA. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of HCA Healthcare in a research note on Monday, January 27th. Royal Bank of Canada lowered their target price on HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating on the stock in a research note on Monday, January 27th. KeyCorp lowered their price objective on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $380.00 target price on shares of HCA Healthcare in a research note on Tuesday, December 17th. Finally, Barclays cut their price objective on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating for the company in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, HCA Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $385.67.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.